Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report)’s stock price reached a new 52-week low on Thursday . The company traded as low as $8.55 and last traded at $8.56, with a volume of 470564 shares. The stock had previously closed at $11.08.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience presently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on RGC
Regencell Bioscience Trading Down 22.7%
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last released its earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGC. Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience during the 4th quarter worth $92,000. Amundi acquired a new stake in shares of Regencell Bioscience in the first quarter valued at about $219,000. Vident Advisory LLC raised its position in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Regencell Bioscience in the fourth quarter worth about $275,000. Finally, Bank of America Corp DE lifted its stake in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after buying an additional 17,143 shares in the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.
Regencell Bioscience Company Profile
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Read More
- Five stocks we like better than Regencell Bioscience
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
